ImmunityBio Inc [NASDAQ: IBRX] closed the trading session at $2.56.
The stocks have a year to date performance of 0.00 percent and weekly performance of 0.00 percent. The stock has been moved at -61.09 percent over the last six months. The stock has performed -48.39 percent around the most recent 30 days and changed -27.27 percent over the most recent 3-months.
If compared to the average trading volume of 6.62M shares, IBRX reached to a volume of 3905228 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about ImmunityBio Inc [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $14.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for ImmunityBio Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 12, 2023. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on August 03, 2022, representing the official price target for ImmunityBio Inc stock.
The Average True Range (ATR) for ImmunityBio Inc is set at 0.28, with the Price to Sales ratio for IBRX stock in the period of the last 12 months amounting to 255.01.
IBRX stock trade performance evaluation
ImmunityBio Inc [IBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by 0.00. With this latest performance, IBRX shares dropped by -48.39% in over the last four-week period, additionally sinking by -61.09% over the last 6 months – not to mention a drop of -42.73% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBRX stock in for the last two-week period is set at 33.10, with the RSI for the last a single of trading hit 32.06, and the three-weeks RSI is set at 35.55 for ImmunityBio Inc [IBRX]. The present Moving Average for the last 50 days of trading for this stock 4.21, while it was recorded at 2.69 for the last single week of trading, and 5.06 for the last 200 days.
ImmunityBio Inc [IBRX]: An insightful look at the core fundamentals
ImmunityBio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.64 and a Current Ratio set at 2.68.
Earnings per share (EPS) analysis for ImmunityBio Inc [IBRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IBRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ImmunityBio Inc go to -1.70%.
ImmunityBio Inc [IBRX]: Institutional Ownership
There are presently around $9.61%, or 36.27%% of IBRX stock, in the hands of institutional investors. The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 13.83 million shares, which is approximately 2.0558%. BLACKROCK INC., holding 11.42 million shares of the stock with an approximate value of $$72.19 million in IBRX stocks shares; and BLACKROCK INC., currently with $$49.7 million in IBRX stock with ownership which is approximately 1.1688%.
